Go to Health Care Provider version
|Diagnosis||Childhood Solid Tumor, Lymphoma, Pediatric Brain Tumor, Other brain tumors, Other solid tumours, Non-Hodgkin lymphoma||Study Status||Open|
|Age||Child, Adult - (1 Year to 21 Years)||Randomisation||NO|
|Line of treatment||First line treatment, Disease relapse or progression|
|Routes of Treatment Administration||oral (capsule)|
|Last Posted Update||2023-03-03|
|ClinicalTrials.gov #||NCT03936465 |
International SponsorDana-Farber Cancer Institute
Principal Investigators for Canadian SitesThe Hospital for Sick Children - Dr. Daniel Morgenstern
This study is to evaluate the drug called BMS-986158 as a possible treatment for pediatric solid tumors, lymphoma, or brain tumors. BMS-986158 belongs to a group of drugs called "Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors". These drugs block proteins from the BET family that are important in reading part of the DNA involved in apoptosis and cell cycle progression. It is expected to slow or stop the growth of cancer cells.
The aim of this phase I study is to evaluate the dose, safety, tolerability, antitumor activity and other pharmacologic characteristics of BMS-986158 in children with refractory or relapsed pediatric solid tumors, lymphoma, or brain tumors for which no standard therapy is available or for which the subject is not eligible for the existing therapy.
Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.